Advancing drug discovery for schizophrenia.
Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.
Semel Institute for Neuroscience at the University of California, Los Angeles, California, USA.
Stephen R
SR
Marder
Bryan
B
Roth
Patrick F
PF
Sullivan
Edward M
EM
Scolnick
Eric J
EJ
Nestler
Mark A
MA
Geyer
Daniel R
DR
Welnberger
Maria
M
Karayiorgou
Alessandro
A
Guidotti
Jay
J
Gingrich
Schahram
S
Akbarian
Robert W
RW
Buchanan
Jeffrey A
JA
Lieberman
P Jeffrey
PJ
Conn
Stephen J
SJ
Haggarty
Amanda J
AJ
Law
Brian
B
Campbell
John H
JH
Krystal
Bita
B
Moghaddam
Akira
A
Sawa
Akira
A
Saw
Marc G
MG
Caron
Susan R
SR
George
John A
JA
Allen
Michelle
M
Solis
D000818:Animals; D014150:Antipsychotic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000302:isolation & purification*; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D057890:Epigenomics / Q000379:methods; D055106:Genome-Wide Association Study; D006801:Humans; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D009518:New York; D012106:Research / Q000639:trends; D012107:Research Design; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics
D014150:Antipsychotic Agents